about
Improving platelet transfusion safety: biomedical and technical considerationsThe PFA-100 detects sub-optimal antiplatelet responses in patients on aspirinGlycoproteins expression on platelet membrane in inherited macrothrombocytopenias.Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.Platelet dose for prophylactic platelet transfusions.[Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group].Severe Babesia microti infection in an American immunocompetent patient diagnosed in Spain.Fatal alloimmune thrombocytopenia due to anti-HLA alloimmunization in a twin pregnancy: A very infrequent complication of assisted reproduction.Quality indicators for Transfusion Medicine in Spain: a survey among hospital transfusion servicesMatching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes.Transfusion medicine as of 2014.Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) studyA prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.The role of red blood cell exchange for severe imported malaria in the artesunate era: a retrospective cohort study in a referral centreTherapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature.Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.Plasma treated with methylene blue and light: clinical efficacy and safety profile.Pathogen inactivation: coming of age.Automation of blood component preparation from whole blood collections.Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.Survival after ultramassive transfusion: a review of 1360 cases.Platelet transfusion and respecting patient D type.Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.An international survey on the role of the hospital transfusion committee.Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey.Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort.Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.Platelet concentrates: Balancing between efficacy and safety?Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease.Internal medicine resident knowledge of transfusion medicine: results from the BEST-TEST international education needs assessment.Automated preparation of whole blood-derived platelets suspended in two different platelet additive solutions and stored for 7 days.The addition of MESNA in vitro prolongs prothrombin time similar to N-acetyl cysteine.Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion-transmissible infections.Comparison of plasma exchange procedures using three apheresis systems.Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.Factors affecting red blood cell storage age at the time of transfusion.Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes.Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion-transmissible infections: summary.Cocaine-induced acute hepatitis and thrombotic microangiopathy.
P50
Q26775408-78FD8C6F-A544-4CE3-BA5F-7D8C179F26E4Q28218417-96E070F2-F0E4-485D-89E0-D9878E882E55Q33359784-EB90E38F-5465-4CBB-BACC-905B50B70CF6Q33374336-CC3A4914-93D9-4131-AABA-29E92DAEF92BQ33392855-88C9CFD6-0CFB-476A-AB28-B5E40E2773E9Q33418938-50525DF2-C1CB-439C-8141-E51A8C2F6297Q33434414-8FFF7F3D-1375-4A85-8CAB-7C9CF6341351Q33436722-5B16E60A-C9C6-4066-92C5-9A2F4A74E70CQ33739495-6DDB957D-21C3-485C-83EC-2CFE888ECC42Q33953403-550919C6-1BBA-41EA-ACFC-1A6F43B2B137Q34500022-C021B531-5219-45A4-9271-043BAE0BB022Q35040235-7F351E5E-A69B-4852-9734-1F23D5DA2F2EQ36402628-56DD313F-989E-4E38-8B8D-DE9010971947Q36796904-002484F1-8901-40A1-88DC-F5EDC51D0F6CQ37875273-364D568A-8198-4E7A-B8A2-20D7EFE6076CQ38096606-DD066B60-D7EB-43C6-BB39-F2F36AA51BD2Q38099101-523DC529-7869-4DAC-8EDF-2F72F469CA43Q38146098-6736CCE9-B276-476E-B3F3-6D5A957081DBQ38150634-56FFBF6E-72EA-40F3-9E51-0480D33C52DAQ38180463-FCAB3677-5244-460A-AEEA-A818FF104361Q38215451-4F1EB689-F5E4-481F-8969-C1E92928240CQ38411977-B6A6FB5A-EE59-4615-B9C0-FDF9894E96E3Q38594433-8AA663A4-00E8-4C7C-A5BC-2DAE4A273095Q38757558-B6634C1B-BAA1-4733-B584-2FDD3D3531A6Q39150162-50277F81-239F-4FF2-8FBB-CD4DE1B843D0Q39874781-A3621D64-78F6-4F09-BC9D-F7A15D878629Q40246892-B754D0AD-7F97-42B5-9AAE-0BA562B60D3EQ40373480-A0DE0BC9-59F3-4A8F-BEAA-0BE5482F1AD6Q40594144-1C1C22EB-35AD-4502-9927-704B37A88342Q40903255-9460B9A3-F813-4366-93DE-4570A07EBD0EQ41671841-ADFD9320-E696-44E9-AFF8-6DD032892C70Q43587730-50255138-5E6E-44A0-99E0-0777DC38F595Q43853723-C515F891-458D-4252-987D-B25E93757160Q43918665-F0D1D66B-F4CD-4453-911A-E093906BBB58Q44496156-150D12F7-1D00-4111-AB83-A5608944AD33Q44834486-42D08069-1FA2-42E3-834B-ABE729C72D8CQ45051724-4CB3E2C4-7164-4074-B1F0-4DD2D9AE73D6Q45194912-9B83D3D8-EADF-4EAA-AE73-09D1A6EA31DBQ45240841-31B4DD70-702F-4F07-8832-365DC8E3C5F9Q45267366-A155608E-3C6F-403A-9C48-465EBAAF5A94
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Miguel Lozano
@ast
Miguel Lozano
@es
Miguel Lozano
@nl
Miguel Lozano
@sl
Miquel Lozano
@en
type
label
Miguel Lozano
@ast
Miguel Lozano
@es
Miguel Lozano
@nl
Miguel Lozano
@sl
Miquel Lozano
@en
altLabel
Miguel Lozano
@en
Miguel Lozano-Molero
@en
prefLabel
Miguel Lozano
@ast
Miguel Lozano
@es
Miguel Lozano
@nl
Miguel Lozano
@sl
Miquel Lozano
@en
P106
P1153
19735998600
6508259495
P21
P27
P31
P496
0000-0003-2593-833X